Is this your business? Claim it to manage your IP and profile
The xT CDx is a state-of-the-art Next Generation Sequencing (NGS) diagnostic tool designed to detect genetic alterations in cancer patients. Utilizing a sample from formalin-fixed paraffin-embedded (FFPE) tissue and matched normal samples, it profiles DNA mutations across 648 genes. This comprehensive profile aids in determining personalized treatment paths and identifies patients eligible for specific therapies as detailed in therapeutic product labeling. The xT CDx not only serves as a companion diagnostic but also provides detailed tumor mutation insights crucial for treatment planning.\n\nOne of the key benefits of the xT CDx is its capability to deliver precision in diagnosis and treatment, leveraging genetic data to engage the most suitable therapies for cancer patients. The ability to identify microsatellite instability and pursue thorough tumor mutation profiling sets a new standard in personalized oncology approaches, ensuring that therapies are tailored down to the genetic level. The technology integrates seamlessly with clinical guidelines, enabling healthcare professionals to make informed, data-driven treatments.\n\nIn the landscape of companion diagnostics, the xT CDx stands out, providing wide-ranging genetic information that surpasses conventional diagnostics. Its application ensures that oncologists have access to the most relevant genetic insights, shaping a more predictive and personalized approach to cancer care. Available as a single-site assay from Tempus Labs in Chicago, the xT CDx embodies a leap forward in how cancer biomarker screening informs and enhances clinical decisions.
The DPYD Test is an advanced genetic screening tool designed to evaluate risk levels associated with toxicity from 5-FU and capecitabine treatments in cancer patients. Through the assessment of the DPYD gene, which encodes the enzyme dihydropyrimidine dehydrogenase, the test identifies patients at heightened risk for serious side effects from these chemotherapies. This is especially critical for addressing adverse effects in colorectal, breast, pancreatic, and other gastrointestinal cancers.\n\nDesigned to support clinical decision-making, the DPYD Test provides a comprehensive genetic profile that includes five specific single nucleotide variants (SNVs) within the DPYD gene. These genetic insights help oncologists to personalize chemotherapy regimens, minimizing the risk of toxicity by identifying patients who may need adjusted dosages or alternative treatments.\n\nThe DPYD Test is available as an add-on to existing Tempus diagnostic tools, amplifying its utility in a clinical setting. By offering expanded toxicity risk assessment without the need for additional tissue samples, it emphasizes convenience and accuracy, ensuring safer and more effective chemotherapy management for patients with cancer.
Intel expands its foundry ecosystem with alliances with TSMC, UMC, and Taiwanese tech partners, marking a major transformation for the firm's production strategy. Read more
Join the world's most advanced semiconductor IP marketplace!
It's free, and you'll get all the tools you need to discover IP, meet vendors and manage your IP workflow!
No credit card or payment details required.
Join the world's most advanced AI-powered semiconductor IP marketplace!
It's free, and you'll get all the tools you need to advertise and discover semiconductor IP, keep up-to-date with the latest semiconductor news and more!
Plus we'll send you our free weekly report on the semiconductor industry and the latest IP launches!
To evaluate IP you need to be logged into a buyer profile. Select a profile below, or create a new buyer profile for your company.